Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences

• Published in: Frontiers in chemistry Vol. 9; p. 802766
• Main Authors: Hegde, Shalakha, Tang, Zhichao, Zhao, Junxing, Wang, Jingxin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.12.2021
• Subjects: antisense oligonucleotide; antiviral; Chemistry; RNA-targeting; SARS-CoV-2; small molecule; untranslated region; SARS-CoV-2; small molecule; RIBOTAC; antisense oligonucleotide; antiviral; programmed frameshift; untranslated region; RNA-targeting
• DOI: 10.3389/fchem.2021.802766
• ISSN: 2296-2646

The ongoing COVID-19/Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) pandemic has become a significant threat to public health and has hugely impacted societies globally. Targeting conserved SARS-CoV-2 RNA structures and sequences essential for viral genome translation is a novel approach to inhibit viral infection and progression. This new pharmacological modality compasses two classes of RNA-targeting molecules: 1) synthetic small molecules that recognize secondary or tertiary RNA structures and 2) antisense oligonucleotides (ASOs) that recognize the RNA primary sequence. These molecules can also serve as a "bait" fragment in RNA degrading chimeras to eliminate the viral RNA genome. This new type of chimeric RNA degrader is recently named ribonuclease targeting chimera or RIBOTAC. This review paper summarizes the sequence conservation in SARS-CoV-2 and the current development of RNA-targeting molecules to combat this virus. These RNA-binding molecules will also serve as an emerging class of antiviral drug candidates that might pivot to address future viral outbreaks.